CLOs on the Move

Insmed

www.insmed.com

 
Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. At Insmed, we are on a mission to transform the lives of patients battling serious rare diseases. We are developing novel, targeted therapies to help serve the critical unmet needs of these patients. In concert with developing therapeutic solutions, we are committed to improving the entire patient experience. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.insmed.com
  • 10 Finderne Ave Building 10
    Bridgewater, NJ USA 08807
  • Phone: 908.977.9900

Executives

Name Title Contact Details
Joshua Marcus
 Senior Counsel, Head of Intellectual Property Profile
Sarah Canberg
 Director, Corporate Counsel Profile

Similar Companies

GTC Biotherapeutics

GTC Biotherapeutics is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

FOB Synthesis

FOB Synthesis is a Kennesaw, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioo Scientific

Bioo Scientific is a Austin, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Melinta

Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

Turn Biotechnologies

Turn Biotechnologies develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. We are focused on reprogramming the epigenome – a network of chemical compounds and proteins that control cell functions by influencing which genes are active – to restore capabilities that are often lost with age.